{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:37:30Z","timestamp":1782603450451,"version":"3.54.5"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,3,15]]},"abstract":"<jats:p> PURPOSE: Relapsed extragonadal germ cell tumors patients (EGGCT) are treated with identical salvage chemotherapy regimens, as are patients with metastatic testicular cancer. This investigation evaluates the results of second-line chemotherapy in nonseminomatous EGGCT and tries to identify prognostic factors for survival. <\/jats:p><jats:p> PATIENTS AND METHODS: We conducted a retrospective review of 142 patients treated at eleven European and American centers between 1975 and 1996. All had received cisplatin-containing regimens as induction treatment. <\/jats:p><jats:p> RESULTS: Twenty-seven of 142 patients (19%) were long-term disease-free, 11% with primary mediastinal and 30% of patients with primary retroperitoneal disease. Median follow-up since start of salvage treatment was 11 months (range, 1 to 157) for all patients and 45 months (range, 6 to 157) for surviving patients. Forty-eight patients (34%) received high dose chemotherapy with autologous bone marrow transplant at relapse, and 10 of these patients (21%) are continuously disease-free. Primary mediastinal location (P = .003), sensitivity to cisplatin (P = .003), elevated \u03b2-HCG at relapse (P = .04), and normal LDH at diagnosis (P = .01) were shown to be significant negative prognostic factors for overall survival in univariate; mediastinal location [relative risk ratios (HR) = 1.9; 95% confidence intervals (CI), 1.2 to 3.0] and sensitivity to cisplatin [HR = 2.4; 95% CI, 1.1 to 5.2] were significant negative prognostic factors in multivariate analysis. <\/jats:p><jats:p> CONCLUSION: Although current salvage strategies will cure between 20% and 50% of recurrent metastatic testicular cancer, relapsed nonseminomatous EGGCT patients appear to have an inferior survival rate, in particular in case of primary mediastinal location. Mediastinal primary tumor and inadequate response to cisplatin-based induction chemotherapy have been identified as independent negative prognostic factors, both associated with an approximately two-fold higher risk for failure of salvage treatment. <\/jats:p>","DOI":"10.1200\/jco.2001.19.6.1641","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:45:54Z","timestamp":1487918754000},"page":"1641-1648","source":"Crossref","is-referenced-by-count":90,"title":["Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis"],"prefix":"10.1200","volume":"19","author":[{"given":"J\u00f6rg T.","family":"Hartmann","sequence":"first","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Nichols","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-P.","family":"Droz","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Horwich","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Gerl","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie D.","family":"Fossa","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Beyer","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Pont","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J.","family":"Schmoll","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"From the Tuebingen University Medical Center II, Tuebingen; Klinikum Gro\u03b2hadern, Munich; Virchow Klinikum, Berlin; University of Halle, Halle, Germany; Indiana University, Indianapolis, IN; Oregon Health Sciences University, Portland, OR; Centre L\u00e9on-Berard, Groupe d\u2019Etude des Tumeurs Uro-Geniales, Lyon, France; Royal Marsden Hospital, Sutton, United Kingdom; The Norwegian Radium Hospital, Oslo, Norway; and Kaiser Franz Josef Spital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-086183","unstructured":"Hainsworth  JD,   Greco  FA:   Extragonadal germ cell tumors and unrecognized germ cell tumors.   Semin Oncol 19:  119,1992-127,"},{"key":"R2-086183","unstructured":"Johnson  DE,   Laneri  JP,   Mountain  CF,  et al:  Extragonadal germ cell tumors.   Surgery 73:  85,1973-90,"},{"key":"R3-086183","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-194203000-00006"},{"key":"R4-086183","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197505)35:5<1453::AID-CNCR2820350533>3.0.CO;2-U"},{"key":"R5-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1290"},{"key":"R6-086183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005173222004"},{"key":"R7-086183","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.1.54"},{"key":"R8-086183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707243370406"},{"key":"R9-086183","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900401)65:7<1641::AID-CNCR2820650731>3.0.CO;2-U"},{"key":"R10-086183","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R11-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"R12-086183","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R13-086183","doi-asserted-by":"crossref","unstructured":"Cox  DR:   Regression models and life tables (with discussion).    J R Stat Soc B 34:  187,1987-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R14-086183","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958020-00004"},{"key":"R15-086183","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2476::AID-CNCR2820661206>3.0.CO;2-D"},{"key":"R16-086183","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690534"},{"key":"R17-086183","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-2-124"},{"key":"R18-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1098"},{"key":"R19-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1223"},{"key":"R20-086183","unstructured":"Beyer  J,   Stenning  S,   Gerl  A,  et al:  High-dose versus conventional first-salvage treatment in nonseminoma:   A matched pair analysis.   Proc Am Soc Clin Oncol 18:  326,1999  (abstr)"},{"key":"R21-086183","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-1-7"},{"key":"R22-086183","doi-asserted-by":"crossref","unstructured":"Josefsen  D,   Ous  S,   Hoie  J,  et al:  Salvage treatment in male patients with germ cell tumours.   Br J Cancer 67:  567,1993-572,","DOI":"10.1038\/bjc.1993.104"},{"key":"R23-086183","doi-asserted-by":"crossref","unstructured":"Delgado  FG,   Tjulandin  SA,   Garin  AM:   Long term results of treatment in patients with extragonadal germ cell tumours.   Eur J Cancer 29A:  1002,1993-1005,","DOI":"10.1016\/S0959-8049(05)80211-4"},{"key":"R24-086183","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910301)67:5<1305::AID-CNCR2820670506>3.0.CO;2-J"},{"key":"R25-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2500"},{"key":"R26-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1390"},{"key":"R27-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2638"},{"key":"R28-086183","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(10)62138-8"},{"key":"R29-086183","doi-asserted-by":"crossref","unstructured":"Wright  CD,   Kesler  KA,   Nichols  CR,  et al:  Primary mediastinal nonseminomatous germ cell tumors:   Results of a multimodality approach.   J Thorac Cardiovasc Surg 99:  210,1990-217,","DOI":"10.1016\/S0022-5223(19)37002-3"},{"key":"R30-086183","doi-asserted-by":"crossref","unstructured":"Dartevelle  P,   Chapelier  A,   Navajas  M,  et al:  Replacement of the superior vena cava with polytetrafluoroethylene grafts combined withresection of mediastinal-pulmonary malignant tumors:   Report of thirteen cases.   J Thorac Cardiovasc Surg 94:  361,1987-366,","DOI":"10.1016\/S0022-5223(19)36248-8"},{"key":"R31-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.682"},{"key":"R32-086183","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(96)70121-6"},{"key":"R33-086183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3450"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.6.1641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:33:08Z","timestamp":1653514388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.6.1641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,15]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,3,15]]}},"alternative-id":["10.1200\/JCO.2001.19.6.1641"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.6.1641","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3,15]]}}}